Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its lead clinical drug candidate ATH434. This patent extends protection until at least 2045, significantly increasing ATH434's commercial value and underpinning the planned initiation of Phase 3 trials in Multiple System Atrophy by the end of 2026. The stren…